Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Market Closed - Nasdaq
Other stock markets
 21:30:01 28/06/2024 BST 		5-day change 1st Jan Change
1.21 USD -11.68% Intraday chart for Inhibikase Therapeutics, Inc. -13.57% -4.72%
06-17 Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease CI
06-05 Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline CI

Evolution of the average Target Price on Inhibikase Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3.4MUE2Vm4ycOPEcrl18gZQHc6RsyoAcfoOMm4HvgdFNY.1PNwvADoqobJQZ7ctYBBGjhwIqryOfGSWY7tM8ByZJysknewE-7wrsAnoQ~4bed5393c1d39b01dbb630430919f030

Analyst Recommendations on Inhibikase Therapeutics, Inc.

HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating MT
Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8 MT
HC Wainwright Starts Inhibikase Therapeutics at Buy With $5 Price Target MT
JonesTrading Downgrades Inhibikase Therapeutics to Hold From Buy MT
INHIBIKASE THERAPEUTICS : JonesTrading Initiates Inhibikase Therapeutics at Buy Rating With $12 Price Target MT
DJ Industrial : US Stocks Drop After Some FOMC Members Signal Earlier Rate Hikes MT
Close Update: US Stocks Decline as Fed Projects Rate Hike Implementation in 2023 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.21 USD
Average target price
15.5 USD
Spread / Average Target
+1,180.99%
High Price Target
23 USD
Spread / Highest target
+1,800.83%
Low Price Target
8 USD
Spread / Lowest Target
+561.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Inhibikase Therapeutics, Inc.

HC Wainwright
Maxim
JonesTrading Institutional Services

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IKT Stock
  4. Consensus Inhibikase Therapeutics, Inc.